StockWatch
·
NUVAMA WEALTH · Q2 FY27 · THE VERDICT

Growth Delivered, Costs Inflating — The Margin Question Looms

Nuvama posted 20%+ top-line growth and reiterated 20–25% wealth flow guidance, but management overstated PAT growth on the call. The real tension: can cost inflation and asset management losses erode the margin upside?

Q2 FY27 resultsNUVAMANuvama Wealth Management Ltd13 Nov 2026 · 6 min read
Reported PAT

₹303.5 Cr

+19.5% YoY

Adjusted PAT (ex venture fund charge)

~₹319.5 Cr

+26% YoY · Operating basis

One-time charge

₹16 Cr

Venture fund closure

Nuvama delivered ₹1,366 crore revenue (+20.4% YoY) and ₹303.5 crore PAT (+19.5% YoY) in Q2 FY27. On the call, management claimed ₹937 crore revenue with 21% growth and 26% PAT expansion. The 46% revenue gap remains unexplained — likely a segment vs. consolidated discrepancy — but the PAT story is clearer: a ₹16 crore one-time venture fund closure charge depressed the net number from ₹319 crore operating PAT. Strip that out, and organic growth is solid. The real question is whether cost inflation at 19% employee-cost growth can be managed within the 20–25% organic growth mandate.

Where the profit came from

Operating PAT of ₹319 crore (+26% YoY) reflects strong operating leverage across wealth, private, asset services, and lending. But a ₹16 crore post-tax charge for venture fund amortization — the closure of a pre-winddown fund with remaining distribution costs — brought net PAT to ₹303.5 crore. Management flagged ₹9–10 crore of unamortized cost spread over the next 12 months, so Q3–Q4 will carry a similar drag. The adjusted operating run-rate is the organic number to track; reported is temporarily depressed.

Q2 FY27 PAT progression, ₹ Cr
-56.282.27220.73359.2319Operating PAT-16Venture fund charge303.5Reported PAT
Operating PAT is the organic run-rate; the venture fund closure is a tail-end of a prior commitment.
Management's claims vs. what holds up

Revenue ₹937 Cr with 21% YoY growth

Consolidated revenue ₹1366.1 Cr, +20.4% YoY; management's ₹937 Cr figure not reconciled

Contradicted

PAT growth 26% on operating side

Operating PAT ₹319 Cr +26% YoY; net PAT ₹303.5 Cr +19.5% YoY post one-time charge

Supported (operating)

Client assets ₹5.5 lakh Cr with 25% growth

Wealth AUM ₹46,000 Cr with 25% YoY growth; supported by ₹3,300 Cr Q2 flows

Supported

Asset services revenue growth 50% YoY

Client assets ₹1.63 lakh Cr, 50% YoY growth; management expects normalization to 4–5%

Supported (acknowledged as exceptional)

What changed on this call

The four big shifts from prior quarter
  • Dividend withheld for H1 FY27 (downgrade) — focus shifted to debt paydown; debt-to-equity target 2.9x → 2.5x

  • Cost-to-income improved 200 bps YoY to ~50%; targeting further 100–200 bps (upgrade) — efficiency gains offsetting headcount adds

  • Asset services revenue 50% YoY but management signals normalization to 4–5% going forward (mixed) — macro normalization baked in

  • Employee cost +19% YoY to ₹382 Cr; ESOP ₹6 Cr/quarter recurring; 250 RM hires planned (downgrade) — structural cost headwind

Organic growth engines — where the 20% came from

Wealth management net flows ₹3,300 crore (Q2 addition), tracking ₹8,300 crore YTD — roughly 11–12% of opening balance, within the 20–25% FY27 guidance range. Lending book ₹6,000 crore (+60% YoY) at stable 2.5% yields. Private wealth ARR assets crossing ₹60–62 lakh crore with ₹5,000 crore new money Q2; transaction income 60–70% recurring monthly. Asset services client assets ₹1.63 lakh crore, though yields normalized to 2.5% post-exceptional Q1 (cash collateral held at 38–40%). Capital markets picked up momentum — 38 IPOs in Q2 vs. 4 in Q1 — but ECM mandates remain ₹85–90 crore revenue range. Asset management AUM ₹12,000 crore still unprofitable; SIF launch expected Nov–Dec (RTA/trustee approvals pending).

The bull-bear ledger

  • 20%+ organic growth across diversified engines (wealth, private, lending, asset services)

  • Cost-to-income improved 200 bps YoY, tracking to beat 55% consolidated target

  • Wealth flows ₹3,300 crore Q2 on track for 20–25% FY27 guidance

  • Consolidated ROE 29%; strong capital efficiency

  • Employee cost +19% YoY; structural headwind offsetting margin upside

  • Asset management unprofitable; path to breakeven opaque; one-time charges persisting

  • Dividend deferred, signaling balance-sheet caution and lower capital return near-term

  • Clearing competition (18–19 domestic players); market-share erosion risk in JV (49% Motilal-Nuvama stake)

  • Capital markets cyclical; IPO pipeline driving Q2 beat but normalization expected

How the street is positioned

The stock trades at ₹1,847.8 (as of 13 Nov 2026), holding above its 20-day SMA (₹1,780), 50-day SMA (₹1,760), and well above the 200-day SMA (₹1,574). Trend is bullish, but RSI of 55.7 suggests neutral momentum — not overbought. The 52-week range is ₹1,096.9–₹2,066 (ATH); current price sits 10.6% below the all-time high, representing a modest drawdown. Volume trend is normal. The bearish surprise: for a growth stock delivering 20%+ organic top-line with a strong FY27 guidance reiteration, a 10% ATH drawdown suggests the market is price-checking the execution risk on cost control and asset management profitability.

Ownership dynamics are bullish: FII holdings rose 2.06 percentage points QoQ to 19.0% (from 16.94% in Q4 FY26), indicating institutional accumulation despite the macro uncertainty and equity market volatility. DII holdings are modest at 8.49%, suggesting domestic institutional interest remains secondary. Promoters hold 53.98%, a slight 0.15pp QoQ decline but structurally stable. Block activity (Pabrai Wagons buy/sell at ₹1,652.50) is balanced and shows no insider distress or conviction selling near the highs.

The FII accumulation into a stock trading 10% below ATH, paired with guidance reiteration, suggests the buy-the-dip narrative is live. But the market is not pricing in a step-change — the lack of a post-result pop (and the 10% drawdown) implies investors are viewing this as a steady-state execution story, not an inflection. That consensus is fair: Nuvama is delivering on its organic growth playbook, but until asset management turns profitable and cost inflation stabilizes, valuation multiple expansion is unlikely.

Ranked risks

Risks, ordered by how much they should concern a holder

Cost inflation (employee +19% YoY, ESOP ₹6 Cr/qtr recurring, ₹25 Cr HO move FY27)

High

Structural headwind that offsets margin upside and constrains 55% cost-to-income target. 250 RM hires planned; attrition risk in competitive wealth/clearing market. Management flagged 100–200 bps further improvement, but 19% employee inflation makes that a stretch.

Asset management unprofitability; SIF launch timeline slipping; path to breakeven unquantified

High

Still loss-making after years of subsidy. Guidance said ₹35–40 Cr peak cumulative loss FY27, but no profitability inflection date given. Delays in SIF (now Nov–Dec vs. prior '25 days') and private credit fund (2–3 months) stretch credibility. AM is a drag on consolidated margins.

Domestic clearing license proliferation (18–19 competitors); Nuvama is 49% JV stake (Motilal-Nuvama)

Medium

Market share erosion risk as new entrants crowd a 6–7% high-touch market. Management claims 15–18% mandate share and 25% new-inflow capture, but execution risk is high. JV structure limits Nuvama's control; competition in clearing could depress clearing revenues.

Management revenue reporting discrepancy (₹937 Cr stated vs. ₹1,366 Cr delivered); lack of clarification

Medium

46% gap raises credibility flags and suggests potential segment/consolidated confusion or outdated guidance. Must be clarified next investor interaction to rebuild trust in management's on-call disclosures.

Capital markets cyclicality (IPO/M&A pipeline dependent); CAS regulations impacting derivatives (-₹2 Cr/month Aug–Sep)

Medium

Q2 beat on 38 IPOs vs. 4 in Q1. Management expects normalization to 4–5% base growth; macro slowdown could worsen. Regulatory headwinds (CAS) to persist; fixed-income yield compression risk if duration increases.

Lending book collateral composition fragility to FPI shocks; yields stable 2.5% but cash collateral at 38–40%

Low

If FPI outflows accelerate, demand for cash collateral could spike, forcing yield compression. Management says yields would hold 2.5–2.8% even with 50% cash collateral, but execution risk on price acceptance is moderate.

The debate

What to watch next

Concrete catalysts for resolution
  • 1 · Asset management SIF approval (Nov–Dec 2026)

    RTA/trustee approvals imminent. If SIF launches on time with credible AUM traction (₹500–750 crore target), AM path to profitability gains credibility. Delay or weak pickup is a red flag.

  • 2 · Q3 cost trajectory (Jan 2027 earnings)

    Employee cost growth, ESOP charge run-rate, and BAU opex adherence to ₹520–550 Cr guidance. Can management sustain 100–200 bps cost-to-income improvement while growing 20%+? Q3 will signal mid-year execution risk.

  • 3 · Dividend reinstatement decision (April 2027)

    Deferred H1 dividend signals debt paydown focus; reinstatement in H2 or April 2027 would signal balance-sheet confidence and unlock capital return narrative. Omission would suggest macro caution persists.

  • 4 · FY27 full-year PAT growth actuals vs. 20%+ implied by guidance

    H1 delivered 19.5% (with one-time charges). H2 must accelerate to hit low 20s; if not, cost inflation or macro headwinds are worse than guided. Organic margin trajectory is the north star.

The number to track

Adjusted operating PAT (ex one-time charges) and cost-to-income ratio. Adjusted operating PAT ~₹319 crore is the organic run-rate; that needs to compound 20%+ YoY for guidance credibility. Cost-to-income ~50% and the management's ability to hold it or improve further despite 19% employee cost inflation is the margin quality test. If adjusted operating PAT growth dips below 18% or cost-to-income creeps back above 51%, the bull case weakens — execution risk on cost control becomes material.

Nuvama delivered a solid quarter: 20%+ top-line growth, reiterated 20–25% wealth flow guidance, and 200 bps cost improvement. The market has priced in the execution case fairly — a 10% ATH drawdown reflects medium-term uncertainty on cost control and asset management profitability, not a panic. This is not a step-change, but steady execution: a high-quality franchise managing margin pressure and funding a multi-year transition. Hold for FY27 catalysts (SIF launch, Q3 cost trajectory, H2 dividend reinstatement). The risk case dominates if H2 adjusted PAT growth slips below 18% or employee cost inflation accelerates further.

Informational and educational content only. Not investment advice.